RxDoctor Payments DataLook up a doctor →

Ernest Thompson, MD

Internal Medicine · Baker, LANPI 1841212610

Payments from drug & device makers

$2,062,024in general payments, 2019–2025

Across 790 payments — averaging $2610.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.5M
  • AstraZeneca$388K
  • Bayer$58K
  • Ortho-clinical Diagnostics, Inc.$52K
  • Teva Pharmaceuticals USA, Inc.$25K
  • Chiesi USA, Inc.$20K
  • plus $31K from 51 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis51$1,487,132
AstraZeneca56$388,087
Bayer55$58,399
Ortho-clinical Diagnostics, Inc.1$52,101
Teva Pharmaceuticals USA, Inc.12$24,656
Chiesi USA, Inc.6$20,393
Alnylam Pharmaceuticals Inc.2$12,598
Sanofi US Services Inc.4$5,790
GSK99$1,694
Amgen64$1,601
AbbVie(2 entities)92$1,520
Valeritas, Inc.25$620
Novo Nordisk25$609
Supernus Pharmaceuticals, Inc.30$471
Pfizer23$458
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)14$452
Boehringer Ingelheim International GmbH2$442
Daiichi Sankyo Inc.13$404
Lilly USA, LLC23$394
Takeda Pharmaceuticals U.S.A., Inc.21$387
Boehringer Ingelheim14$328
Abbott12$311
Astellas Pharma US Inc13$309
Vanda Pharmaceuticals Inc.11$304
Johnson & Johnson10$230
E.r. Squibb & Sons, L.L.C.12$228
Dexcom, Inc.6$217
Ardelyx, Inc.9$161
Otsuka America Pharmaceutical, Inc.3$160
Avanir Pharmaceuticals, Inc.8$150
Merck11$149
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$138
Lundbeck LLC8$133
Axsome Therapeutics, Inc.6$125
Sanofi-aventis U.S. LLC5$120
Amarin Pharma, Inc.5$82
Exact Sciences4$70
Jazz Pharmaceuticals Inc.3$66
Kowa Pharmaceuticals America, Inc.3$50
Embecta Corp.3$49
Sanofi1$44
Insulet Corporation2$42
Idorsia Pharmaceuticals US Inc2$40
Medtronic(2 entities)2$38
Arbor Pharmaceuticals, Inc.2$30
Mannkind Corporation2$30
Neurocrine Biosciences, Inc.1$28
Eisai Inc.1$24
Philips North America LLC1$23
Corcept Therapeutics1$20
Shield Therapeutics Inc1$19
Adlon Therapeutics L.p.1$18
Antares Pharma, Inc.1$18
UCB, Inc.1$16
Shire North American Group Inc1$16
Xeris Pharmaceuticals, Inc.1$15
Currax Pharmaceuticals LLC1$14

How this compares

$2,062,024 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$208,001
Medicare patients
355
Services billed
3,353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Baker

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →